Evolution of the Lipid Trial Protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial

• Published in: The American journal of cardiology 2007-06, Vol.99 (12), p.S56-S67
• Main Authors: Ginsberg, Henry N., MD, Bonds, Denise E., MD, MPH, Lovato, Laura C., MS, Crouse, John R., MD, Elam, Marshall B., MD, PhD, Linz, Peter E., MD, O’Connor, Patrick J., MPH, MD, Leiter, Lawrence A., MD, Weiss, Daniel, MD, CDE, Lipkin, Edward, MD, PhD, Fleg, Jerome L., MD
• Format: Article
• Language: English
• Subjects: Cardiology; Cardiovascular; Cardiovascular disease; Clinical outcomes; Clinical trials; Coronary Artery Disease - blood; Coronary Artery Disease - prevention & control; Diabetes; Diabetes Mellitus, Type 2; Diabetic Angiopathies - blood; Diabetic Angiopathies - prevention & control; Drug Administration Schedule; Drug therapy; Fenofibrate - therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hyperlipidemias - blood; Hyperlipidemias - prevention & control; Hypolipidemic Agents - therapeutic use; Inhibitor drugs; Lipids; Randomized Controlled Trials as Topic; Research Design; Risk factors; Statins
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2007.03.024

The Action to Control Cardiovascular Risk in Diabetes (ACCORD) lipid trial aims to test whether a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) plus a fibrate is more efficacious in reducing cardiovascular events than a statin plus placebo in patients with type 2 diabetes mellitus with defined glycemic control. This is a blinded component in a 5,518-patient subset of the ACCORD cohort. These participants were randomized to either be (1) treated with simvastatin (titrated to 40 mg/day if necessary to achieve a goal low-density lipoprotein [LDL] cholesterol level of